LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
复制标题

DOI:
10.4161/epi.4.3.8694
复制
发表时间:
2009-04-01
期刊:
影响因子:
3.7
通讯作者:
Issa JP
Issa JP
中科院分区:
生物学3区
文献类型:
--
作者:
Aparicio A;North B;Barske L;Wang X;Bollati V;Weisenberger D;Yoo C;Tannir N;Horne E;Groshen S;Jones P;Yang A;Issa JP

文献摘要

参考文献

被引文献

相似文献

Multiple clinical trials are investigating the use of the DNA methylation inhibitors azacitidine and decitabine for the treatment of solid tumors. Clinical trials in hematological malignancies have shown that optimal activity does not occur at their maximum tolerated doses but selection of an optimal biological dose and schedule for use in solid tumor patients is hampered by the difficulty of obtaining tumor tissue to measure their activity. Here we investigate the feasibility of using plasma DNA to measure the demethylating activity of the DNA methylation inhibitors in patients with solid tumors. We compared four methods to measure LINE-1 and MAGE-A1 promoter methylation in T24 and HCT116 cancer cells treated with decitabine treatment and selected Pyrosequencing for its greater reproducibility and higher signal to noise ratio. We then obtained DNA from plasma, peripheral blood mononuclear cells, buccal mucosa cells and saliva from ten patients with metastatic solid tumors at two different time points, without any intervening treatment. DNA methylation measurements were not significantly different between time point 1 and time point 2 in patient samples. We conclude that measurement of LINE-1 methylation in DNA extracted from the plasma of patients with advanced solid tumors, using Pyrosequencing, is feasible and has low within patient variability. Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA.
DOI: 10.1196/annals.1448.050
发表时间: 2008-01-01
期刊: CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V
影响因子: --
作者:
Gahan, Peter B.;Swaminathan, R.
通讯作者: Swaminathan, R.
DOI: 10.1158/0008-5472.can-05-2385
发表时间: 2006-05-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Yang, Allen S.;Doshi, Ketan D.;Issa, Jean-Pierre J.
通讯作者: Issa, Jean-Pierre J.
DOI: 10.1093/nar/25.12.2529
发表时间: 1997-06-15
影响因子: 14.9
作者:
Gonzalgo, ML;Jones, PA
通讯作者: Jones, PA
DOI: 10.1196/annals.1368.040
发表时间: 2006-01-01
期刊: CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM IV
影响因子: --
作者:
Umetani, Nayuk;Hiramatsu, Suzanne;Hoon, Dave S. B.
通讯作者: Hoon, Dave S. B.
DOI: 10.1200/jco.2005.06.118
发表时间: 2005-06-10
影响因子: 45.3
作者:
Samlowski, WE;Leachman, SA;Karpf, AR
通讯作者: Karpf, AR